Top Tweets for #LuParp
#LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with #mCRPC. Presentation by @SandhuShahneen @PeterMacCC. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > https://t.co/qpP48yqyNi @myESMO @neerajaiims
π’ #ASCOGU25 | #LuPARP
π¬ LuPARP: [ΒΉβ·β·Lu]Lu-PSMA-617 + Olaparib in mCRPC
Presented by Sandhu S
@OncoAlert
π Key Results:
β
PSA50: 66% (21/32) π
β
PSA30: 53% (17/32)
β
ORR by RECIST 1.1: 44% (14/32)
π« Toxicity: No DLTs or grade 4 AEs. Main AE: febrile neutropenia.
π Conclusion: Lu-PSMA + Olaparib shows promising activity in mCRPC with a manageable safety profile.
@montypal
@crisbergerot
@DrDanielHeng
@apolo_andrea
@DrChoueiri
@PGrivasMDPhD
@TiansterZhang
@HHammersMD
@ravikanesvaran
@neerajaiims
@amerseburger
@sonpavde
@drenriquegrande
@scserendipity1
@Silke_Gillessen
@EfstathiouEleni
@tompowles1
@BraunMDPhD
@cdanicas
@DrYukselUrun
@seanmmcbride
@gu_onc
@declangmurphy
@VincentWenxinXu
@RenuEapen
@APCCC_Lugano
π₯ @ASCO @OncoAlert #GUcancer #ProstateCancer #Theranostics #LuPARP
![nataliagandur's tweet photo. π’ #ASCOGU25 | #LuPARP
π¬ LuPARP: [ΒΉβ·β·Lu]Lu-PSMA-617 + Olaparib in mCRPC
Presented by Sandhu S
@OncoAlert
π Key Results:
β
PSA50: 66% (21/32) π
β
PSA30: 53% (17/32)
β
ORR by RECIST 1.1: 44% (14/32)
π« Toxicity: No DLTs or grade 4 AEs. Main AE: febrile neutropenia.
π Conclusion: Lu-PSMA + Olaparib shows promising activity in mCRPC with a manageable safety profile.
@montypal
@crisbergerot
@DrDanielHeng
@apolo_andrea
@DrChoueiri
@PGrivasMDPhD
@TiansterZhang
@HHammersMD
@ravikanesvaran
@neerajaiims
@amerseburger
@sonpavde
@drenriquegrande
@scserendipity1
@Silke_Gillessen
@EfstathiouEleni
@tompowles1
@BraunMDPhD
@cdanicas
@DrYukselUrun
@seanmmcbride
@gu_onc
@declangmurphy
@VincentWenxinXu
@RenuEapen
@APCCC_Lugano
π₯ @ASCO @OncoAlert #GUcancer #ProstateCancer #Theranostics #LuPARP](https://pbs.twimg.com/media/GjsCtD5acAAJNuY.jpg)
![nataliagandur's tweet photo. π’ #ASCOGU25 | #LuPARP
π¬ LuPARP: [ΒΉβ·β·Lu]Lu-PSMA-617 + Olaparib in mCRPC
Presented by Sandhu S
@OncoAlert
π Key Results:
β
PSA50: 66% (21/32) π
β
PSA30: 53% (17/32)
β
ORR by RECIST 1.1: 44% (14/32)
π« Toxicity: No DLTs or grade 4 AEs. Main AE: febrile neutropenia.
π Conclusion: Lu-PSMA + Olaparib shows promising activity in mCRPC with a manageable safety profile.
@montypal
@crisbergerot
@DrDanielHeng
@apolo_andrea
@DrChoueiri
@PGrivasMDPhD
@TiansterZhang
@HHammersMD
@ravikanesvaran
@neerajaiims
@amerseburger
@sonpavde
@drenriquegrande
@scserendipity1
@Silke_Gillessen
@EfstathiouEleni
@tompowles1
@BraunMDPhD
@cdanicas
@DrYukselUrun
@seanmmcbride
@gu_onc
@declangmurphy
@VincentWenxinXu
@RenuEapen
@APCCC_Lugano
π₯ @ASCO @OncoAlert #GUcancer #ProstateCancer #Theranostics #LuPARP](https://pbs.twimg.com/media/GjsCtDXacAUtOdl.jpg)
![nataliagandur's tweet photo. π’ #ASCOGU25 | #LuPARP
π¬ LuPARP: [ΒΉβ·β·Lu]Lu-PSMA-617 + Olaparib in mCRPC
Presented by Sandhu S
@OncoAlert
π Key Results:
β
PSA50: 66% (21/32) π
β
PSA30: 53% (17/32)
β
ORR by RECIST 1.1: 44% (14/32)
π« Toxicity: No DLTs or grade 4 AEs. Main AE: febrile neutropenia.
π Conclusion: Lu-PSMA + Olaparib shows promising activity in mCRPC with a manageable safety profile.
@montypal
@crisbergerot
@DrDanielHeng
@apolo_andrea
@DrChoueiri
@PGrivasMDPhD
@TiansterZhang
@HHammersMD
@ravikanesvaran
@neerajaiims
@amerseburger
@sonpavde
@drenriquegrande
@scserendipity1
@Silke_Gillessen
@EfstathiouEleni
@tompowles1
@BraunMDPhD
@cdanicas
@DrYukselUrun
@seanmmcbride
@gu_onc
@declangmurphy
@VincentWenxinXu
@RenuEapen
@APCCC_Lugano
π₯ @ASCO @OncoAlert #GUcancer #ProstateCancer #Theranostics #LuPARP](https://pbs.twimg.com/media/GjsCtDXacAMt2TA.jpg)
![nataliagandur's tweet photo. π’ #ASCOGU25 | #LuPARP
π¬ LuPARP: [ΒΉβ·β·Lu]Lu-PSMA-617 + Olaparib in mCRPC
Presented by Sandhu S
@OncoAlert
π Key Results:
β
PSA50: 66% (21/32) π
β
PSA30: 53% (17/32)
β
ORR by RECIST 1.1: 44% (14/32)
π« Toxicity: No DLTs or grade 4 AEs. Main AE: febrile neutropenia.
π Conclusion: Lu-PSMA + Olaparib shows promising activity in mCRPC with a manageable safety profile.
@montypal
@crisbergerot
@DrDanielHeng
@apolo_andrea
@DrChoueiri
@PGrivasMDPhD
@TiansterZhang
@HHammersMD
@ravikanesvaran
@neerajaiims
@amerseburger
@sonpavde
@drenriquegrande
@scserendipity1
@Silke_Gillessen
@EfstathiouEleni
@tompowles1
@BraunMDPhD
@cdanicas
@DrYukselUrun
@seanmmcbride
@gu_onc
@declangmurphy
@VincentWenxinXu
@RenuEapen
@APCCC_Lugano
π₯ @ASCO @OncoAlert #GUcancer #ProstateCancer #Theranostics #LuPARP](https://pbs.twimg.com/media/GjsCtDUbAAAy4fp.jpg)
#LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration-resistant #ProstateCancer #mCRPC. Presentation by @SandhuShahneen @PeterMacCC. #ASCO23 written coverage by @RKSayyid @UofT > https://t.co/bZdreX4eTO @ASCO
New combinations in #mCRPC: PARPi+PSMA?
#LuPARP trial: Ph1 evaluating Lu-PSMA617 with Olaparib showing promising activity in heavily pretreated cohort:
-PSA RR 66% across dose levels
-PSA >/90% response 44%
-ORR 78%
-No DL toxicities
@SandhuShahneen
@OncoAlert
@PCFnews
π Brilliant discussion!!! πππ
DDR and PARP Inhibition: What's the Damage?
β¨DO MOLECULAR TESTING!! β¨
@vanderweelemd @ASCO #ASCO23 @OncoAlert
@urotoday #LuPARP
Eloquent discussion by @SandhuShahneen
#LuPARP : Lu-PSMA-617 + olaparib is well tolerated and has promising clinical activity in #mCRPC
@OncoAlert #ASCO23
Circulating tumor cells in patients with #mCRPC treated with olaparib + 177Lu-PSMA-617 in the #LuPARP trial. Presentation by @anis_a_hamid @DanaFarber_GU. #ASCO23 written coverage by @RKSayyid @UofT > https://t.co/z7WlubEMZp @ASCO
Looking forward to #ASCO23 presentation by @SandhuShahneen @PeterMacCC - #LuPARP: Phase 1 trial of 177Lu-PSMA-617 and #olaparib in patients w/ metastatic castration-resistant #ProstateCancer #mCRPC. Don't miss written coverage following on UroToday! https://t.co/JohbdZbjLm @ASCO
@SandhuShahneen to present #LuPARP results (LuPSMA-617 in combination with olaparib) at #ASCO23 @SandhuShahneen @PCF_Science
Prof @drlouiseemmett on everything #prostatecancer #theranostics. @pros_tic @gu_onc is very well represented ππ». #PRINCE #LuPARP #EVOLUTION #LuTectomy #TheraP | @ANZUPtrials @USANZUrology
@RenoHemonc @DrMHofman @ANZUPtrials @Prof_IanD @ANSTO @TrialsCentre @adacap_news @MovemberAUS @PeterMacCC We have trials of both LuPSMA with PARPi and pembro ongoing #LuPARP @PCF_Science #PRINCE. We have also just opened trials for de novo mHSPC and LuPSMA prior to RP #UpFront #LuTectomy
@soulehoward1 @boragurel @asxlongtail @jodebon @PCF_Science @DrMHofman @nhbander @EUplatinum @ICR_London @LoebStacy @BanderNeil @DrScottTagawa @michael_gorin @pienta_brady @PCFnews @gu_onc Thanks Howard. @PCF_Science funded #LuParp study now recruiting @PeterMacCC @gu_onc - good question to ask in this space with very nice correlative work @DrMHofman A/Prof Sandhu @PeterMacRes
Proud to see the #LuPARP trial finally open @PeterMacCC- the product of my time at @ACORDISM #ACORD2018
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
118.9M followers
Cristiano Ronaldo
@cristiano
114.6M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers